Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Genelux (NASDAQ: GNLX) announced that Thomas Zindrick, President, CEO and Chairman, and Matt Pulisic, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York.
A live webcast will be available during the event and an archived replay will be posted on the company's investor website at https://investors.genelux.com/.
Positive
- None.
Negative
- None.
News Market Reaction – GNLX
In the Nov 26 session, GNLX gained 5.67%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference participation | Neutral | +5.7% | Announcement of Piper Sandler healthcare conference fireside chat and webcast access. |
| Nov 05 | Earnings update | Neutral | -3.3% | Q3 2025 financials, cash of $21.0M, and updated trial timelines. |
| Sep 02 | Conference participation | Neutral | -1.8% | H.C. Wainwright fireside chat and investor meetings announcement. |
| Aug 07 | Earnings update | Neutral | -5.7% | Q2 2025 results, $28.1M cash and OnPrime Phase 3 timing. |
| Jul 07 | Management change | Positive | -2.7% | Appointment of Eric Groen as General Counsel and Head of Business Development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent GNLX news, including earnings and conference participation, has most often seen modest price moves that generally align with neutral or slightly positive news tone, with one management appointment drawing a negative reaction.
Over the last six months, GNLX has reported quarterly results, added senior leadership, and actively participated in investor conferences. Q2 and Q3 2025 earnings updates emphasized cash runway into Q3 2026 and progress of the OnPrime Phase 3 trial. Management changes in July 2025 and multiple fireside chats in September and November 2025 show a focus on corporate development and investor outreach. Today’s conference‑participation news continues that pattern of engagement rather than introducing new clinical or financial data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 12:00 p.m. ET in New York, NY.
A live webcast of the fireside chat can be found here. Following the live webcast, an archived replay will be available on the Company’s website https://investors.genelux.com/.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on X @Genelux_Corp and on LinkedIn.
Investor Contact
Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com
Media Contact
Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com
Source: Genelux Corporation
